Treatment of Murine Colitis by Lactococcus lactis Secreting Interleukin-10

See allHide authors and affiliations

Science  25 Aug 2000:
Vol. 289, Issue 5483, pp. 1352-1355
DOI: 10.1126/science.289.5483.1352

You are currently viewing the abstract.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


The cytokine interleukin-10 (IL-10) has shown promise in clinical trials for treatment of inflammatory bowel disease (IBD). Using two mouse models, we show that the therapeutic dose of IL-10 can be reduced by localized delivery of a bacterium genetically engineered to secrete the cytokine. Intragastric administration of IL-10–secretingLactococcus lactis caused a 50% reduction in colitis in mice treated with dextran sulfate sodium and prevented the onset of colitis in IL-10−/− mice. This approach may lead to better methods for cost-effective and long-term management of IBD in humans.

  • * To whom correspondence should be addressed. E-mail: lothar.steidler{at}

  • These authors contributed equally to this work.

View Full Text

Stay Connected to Science